Advertisement
Research Article| Volume 14, ISSUE 2, P367-391, June 1994

Therapy Other Than Reverse Transcriptase Inhibitors for HIV Infection

  • Joan C. Kaplan
    Correspondence
    Address reprint requests to Joan C. Kaplan, PhD, Infectious Disease Unit, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129.
    Affiliations
    From the Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
  • Martin S. Hirsch
    Affiliations
    From the Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30384-6
Therapy Other Than Reverse Transcriptase Inhibitors for HIV Infection
Previous ArticleIn Situ Polymerase Chain Reaction and HIV-1
Next ArticleHIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring
      This paper is only available as a PDF. To read, Please Download here.
      Antiretroviral drugs against HIV infection have been developed that inhibit various stages of the HIV replication cycle. Agents other than reverse transcriptase inhibitors are reviewed with particular attention to those under study in clinical trials, including inhibitors of the virus-encoded protease enzyme. In addition, innovative strategies using gene therapy are described. It is concluded that combinations of agents may be the best approach for minimizing toxicity and reducing or delaying the emergence of drug-resistant virus during therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Agrawal S.
        • Goodchild J.
        • Civeira M.P.
        • et al.
        Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.
        Proc Natl Acad Sci USA. 1988; 85: 7079-7083
        • Agrawal S.
        • Ikeuchi T.
        • Sun D.
        • et al.
        Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligonucleotides and their phosphorothioate analogues.
        Proc Natl Acad Sci USA. 1989; 86: 7790-7794

      3. Agrawal S, Tang JY: GEM 91-therapeutic agent for AIDS based on antisense oligonucleotide principle [abstract WS-A17-4]. In Programs and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 33

        • Agrawal S.
        • Temsamani J.
        • Tang J-Y
        Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
        Proc Natl Acad Sci USA. 1991; 88: 7595-7599
        • Ashorn P.
        • Englund K.
        • Martin M.A.
        • et al.
        Anti-HIV activity of CD4-pseudomonas exotoxin on infected primary human lymphocytes and monocytes/macrophages.
        J Infect Dis. 1991; 163: 703-709
        • Ashorn P.
        • Moss B.
        • Berger E.A.
        Activity of CD4-pseudomonas exotoxin against cells expressing diverse forms of HIV and SIV envelope glycoproteins.
        J AIDS. 1992; 5: 70-77
        • Ashorn P.
        • Moss B.
        • Weinstein J.N.
        • et al.
        Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-pseudomonas exotoxin and reverse transcriptase inhibitors.
        Proc Natl Acad Sci USA. 1990; 87: 8889-8893
        • Balotta C.
        • Lusso P.
        • Crowley R.
        • et al.
        Antisense phosphorothioate oligodeoxynucleotides targeted to the vpv gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages.
        J Virol. 1993; 67: 4409-4414
        • Baltimore D.
        Intracellular immunization.
        Nature (London). 1988; 329: 219-222
        • Berger E.A.
        • Clouse K.A.
        • Chaudhary V.K.
        • et al.
        CD4-pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.
        Proc Natl Acad Sci USA. 1989; 86: 9539-9543
        • Berkhout B.
        • Silverman R.
        • Jeang K.T.
        Tat transactivates the human immunodeficiency virus through a nascent RNA target.
        Cell. 1989; 59: 273-282
        • Bevec D.
        • Dobrovnik M.
        • Hauber J.
        • et al.
        Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative rev transactivator.
        Proc Natl Acad Sci USA. 1992; 89: 9870-9874
        • Blundell T.
        • Pearl L.
        Retroviral proteinases: A second front against AIDS.
        Nature (London). 1989; 337: 596-597
        • Boiziau C.
        • Thuong N.T.
        • Toulme J-J
        Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.
        Proc Natl Acad Sci USA. 1992; 89: 768-772

      15. Bryant M, Mueller R, Partis R, et al: Efficacy and safety of α-glucosidase inhibitor prodrug SC-49483 in Rhesus monkeys infected with SIV [abstract WS-A11-2]. In Programs and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 27

      16. Bryant M, Mueller R, Smidt M, et al: Anti-HIV properties of α-glucosidase inhibitor SC-48334, the active component of prodrug SC-49483 [abstract WS-A17-6]. In Program and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 33

        • Bryant M.
        • Ratner L.
        Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
        Proc Natl Acad Sci USA. 1990; 87: 523-527
        • Bryant M.L.
        • Heuckeroth R.O.
        • Kimata J.T.
        • et al.
        Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid.
        Proc Natl Acad Sci USA. 1989; 86: 8655-8659
        • Bryant M.L.
        • Ratner L.
        • Duronio R.J.
        • et al.
        Incorporation of 12-methoxydecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
        Proc Natl Acad Sci USA. 1991; 88: 2055-2059
        • Buck H.M.
        • Koole L.H.
        • Van Genderen M.H.P.
        • et al.
        Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity.
        Science. 1990; 248: 208-212
        • Bushman F.D.
        • Craigie R.
        Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA.
        Proc Natl Acad Sci USA. 1991; 88: 1339-1343
        • Bushman F.D.
        • Fujiwara T.
        • Craigie R.
        Retroviral DNA integration directed by HIV integration protein in vitro: Specific cleavage and integration of HIV DNA.
        Science. 1990; 249: 1555-1558
        • Buzayan J.M.
        • Gerlach W.L.
        • Bruening G.
        Satellite tobacco ringspot virus RNA: A subset of the RNA sequence is sufficient for autolytic processing.
        Proc Natl Acad Sci USA. 1986; 83: 8859-8862
        • Byrn R.A.
        • Mordenti J.
        • Lucas C.
        • et al.
        Biological properties of a CD4 immunoadhesin.
        Nature (London). 1990; 344: 667-670
        • Capon D.J.
        • Chamow S.M.
        • Mordenti J.
        • et al.
        Designing CD4 immunoadhesins for AIDS therapy.
        Nature. 1989; 337: 525-531
        • Chang D.D.
        • Sharp P.A.
        Messenger RNA transport and HIV rev regulation.
        Science. 1990; 249: 614-615
        • Chatterjee S.
        • Johnson P.R.
        • Wong J.K.K.
        Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.
        Science. 1992; 258: 1485-1488
        • Chaudhary V.K.
        • Mizukami T.
        • Fuerst T.R.
        Selective killing of HIV-infected cells by recombinant human CD4-pseudomonas exotoxin hybrid protein.
        Nature (London). 1988; 335: 369-372
        • Chen J-C
        • Banerjea A.C.
        • Harmison G.G.
        • et al.
        Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates.
        Nucleic Acids Res. 1992; 20: 4581-4589
        • Chiu I-M
        • Yaniv A.
        • Dahlberg J.E.
        • et al.
        Nucleotide sequence evidence for the relationship of AIDS retrovirus to lentiviruses.
        Nature (London). 1985; 317: 366-368
        • Chow S.A.
        • Vincent K.A.
        • Ellison V.
        • et al.
        Reversal of integration and DNA splicing mediated by integrase of human imunodeficiency virus.
        Science. 1992; 255: 723-726
        • Constantoulakis P.
        • Campbell M.
        • Felber B.K.
        • et al.
        Inhibition of Rev-mediated HIV-1 expression by an RNA binding protein encoded by the interferon-inducible 9-27 gene.
        Science. 1993; 259: 1314-1318
        • Craig J.C.
        • Duncan I.B.
        • Hockley D.
        • et al.
        Antiviral properties of Ro31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.
        Antiviral Res. 1991; 16: 295-305
        • Craig J.C.
        • Duncan I.B.
        • Jacobsen H.
        • et al.
        In vitro studies on resistance to the HIV proteinase inhibitor Ro 31-8959.
        in: Program and Abstracts of the Second International Workshop on HIV Drug-Resistance. Noordwijk, The Netherlands1993: 22
        • Craigie R.
        • Mizuuchi K.
        • Bushman F.D.
        • et al.
        A rapid in vitro assay for FIIV DNA integration.
        Nucleic Acids Res. 1991; 19: 2729-2734
        • Daar E.S.
        • Li X-L
        • Moudgil T.
        • et al.
        High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
        Proc Natl Acad Sci USA. 1990; 87: 6574-6578
        • Dalgleish A.G.
        • Beverley P.C.
        • Claphan P.R.
        • et al.
        The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
        Nature (London). 1984; 312: 763-767
        • Danos O.
        • Mulligan R.C.
        Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.
        Proc Natl Acad Sci USA. 1988; 85: 6460-6464
        • DeBouck C.
        The HIV-1 protease as a therapeutic target for AIDS.
        AIDS Res Hum Retroviruses. 1992; 8: 153-164
        • Dedera D.
        • Vander Heyden N.
        • Ratner L.
        Attenuation of HIV-1 infectivity by an inhibitor of oligosaccharide processing.
        AIDS Res Hum Retroviruses. 1990; 6: 785-794
        • Deen K.C.
        • McDougal J.S.
        • Inacker R.
        • et al.
        A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
        Nature (London). 1988; 331: 82-84

      42. Delfraissy JF, Sereni D, Brun-Vezinet F, et al: A phase 1-11 dose ranging study of the safety and activity of Ro 31-8959 (HIV-proteinase inhibitor) in previously zidovudine (ZDV) treated HIV-infected individuals [abstract WS-B26-3]. In Program and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 69

        • Desjarlais R.T.
        • Seibel G.L.
        • Kuntz I.D.
        • et al.
        Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.
        Proc Natl Acad Sci USA. 1990; 87: 6644-6648
        • Devadas B.
        • Lu T.
        • Katoh A.
        • et al.
        Substrate specificity of Saccharomyces cerevisiae myristoyl-CoA: protein N-myristoyltransferase: Analysis of fatty acid analogs containing carbonyl groups, nitrogen heteroatoms, and nitrogen heterocycles in an in vitro enzyme assay and subsequent identification of inhibitors of human immunodeficiency virus 1 replication.
        J Biol Chem. 1992; 267: 7224-7239
        • Dewit R.
        • Schattenkerk J.K.M.E.
        • Boucher C.A.B.
        • et al.
        Clinical and virological effects of interferon-a in disseminated AIDS-related Kaposi’s sarcoma.
        Lancet. 1988; 2: 1214-1217
        • Dreyer G.B.
        • Metcalf B.W.
        • Tomaszek Jr, T.A.
        • et al.
        Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors.
        Proc Natl Acad Sci USA. 1989; 86: 9752-9756
        • Dropulic B.
        • Lin N.H.
        • Martin M.A.
        • et al.
        Functional characterization of a U5 ribozyme intracellular suppression of human immunodeficiency virus type 1 expression.
        J Virol. 1992; 66: 1432-1441
        • Engelman A.K.
        • Mizuuchi K.
        • Craigie R.
        HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer.
        Cell. 1991; 67: 1211-1221
        • Erickson J.
        • Neidhart D.J.
        • Van Drie J.
        • et al.
        Design, activity, and 2.8 angstrom crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
        Science. 1990; 249: 527-533
        • Feinberg M.B.
        • Trono D.
        Intracellular immunization: Trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication.
        AIDS Res Hum Retroviruses. 1992; 8: 1013-1022
        • Fernie B.F.
        • Poli G.
        • Fauci A.S.
        Alpha-interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphotropic cells.
        J Virol. 1991; 65: 3968-3971
        • Fesen M.R.
        • Kohn K.W.
        • Leteutre F.
        • et al.
        Inhibitors of human immunodeficiency virus integrase.
        Proc Natl Acad Sci USA. 1993; 90: 2399-2403
        • Fischl M.A.
        • Uttamchandari R.B.
        • Resnick L.
        • et al.
        A phase I study of recombinant human interferon alpha 2α or human lymphoblastoid interferon 2n 1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma.
        J AIDS. 1991; 4: 1-10
        • Fisher R.A.
        • Bertonis J.M.
        • Meier W.
        • et al.
        HIV infection is blocked in vitro by recombinant soluble CD4.
        Nature (London). 1988; 331: 76-78
        • Forster A.C.
        • Symons R.H.
        Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites.
        Cell. 1987; 49: 211-220
        • Fujiwara T.
        • Mizuuchi K.
        Retroviral DNA integration: Structures of an integration intermediate.
        Cell. 1988; 54: 497-504
        • Gendelman H.E.
        • Baca L.M.
        • Turpin J.
        • et al.
        Regulation of HIV regulation in infected monocytes by IFN-a: Mechanisms for viral restriction.
        J Immunol. 1990; 145: 2669-2676
        • Goodchild J.
        • Kohli V.
        Ribozymes that cleave an RNA sequence from human immunodeficiency virus: The effect of flanking sequence on rate.
        Arch Biochem Biophys. 1991; 284: 386-391
        • Goodchild J.
        • Sudhir A.
        • Civeira M.P.
        • et al.
        Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.
        Proc Natl Acad Sci USA. 1988; 85: 5507-5511
        • Gottlinger H.G.
        • Sodroski J.G.
        • Haseltine W.A.
        Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
        Proc Natl Acad Sci USA. 1989; 86: 5781-5785
        • Green M.
        • Ishino M.
        • Loewenstein P.M.
        Mutational analysis of HIV-1 tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.
        Cell. 1989; 58: 215-223
        • Grossman Z.
        • Mendelson E.
        • Brok-Simoni F.
        • et al.
        Detection of adeno-associated virus type 2 in human peripheral blood cells.
        J Gen Virol. 1992; 73: 961-966
        • Hampel A.
        • Tritz R.
        RNA catalytic properties of the minimum (−) s TRSV sequence.
        Biochemistry. 1989; 28: 4929-4933
        • Hansen B.D.
        • Nara P.L.
        • Maheshwari R.K.
        • et al.
        Loss of infectivity by progeny virus from alpha-interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gpl20.
        J Virol. 1992; 66: 7543-7548
        • Harbison M.A.
        • Gillis J.M.
        • Pinkston P.
        • et al.
        Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages.
        J Infect Dis. 1990; 161: 1-6
        • Hartshorn K.L.
        • Vogt M.W.
        • Chou T.C.
        • et al.
        Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.
        Antimicrob Agents Chemother. 1987; 31: 168-172
        • Haseloff J.
        • Gerlach W.L.
        Simple RNA enzymes with new and highly specific endoribonuclease activities.
        Nature (London). 1988; 334: 585-591

      68. Haubrich RH and ACTG Team A213: A randomized study of safety, tolerance, pharmacokinetics and activity of oral Ro 24-7429 (Tat antagonist) in patients with HIV infection [abstract WS-B26-5]. In Program and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 69

        • Heidenreich O.
        • Eckstein F.
        Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1.
        J Biol Chem. 1992; 267: 1904-1909
        • Herskowitz I.
        Functional inactivation of genes by dominant negative mutations.
        Nature (London). 1987; 329: 219-222
        • Heuckeroth R.O.
        • Glaser L.
        • Gordon J.I.
        Heteroatom-substituted fatty acid analogs as substrates for N-myristoyl transferase: An approach for studying both the enzymology and function of protein acylation.
        Proc Natl Acad Sci USA. 1988; 85: 8795-8799
        • Ho D.D.
        C2 symmetric inhibitors of HIV-1 protease and viral resistance.
        in: Program and Abstracts of the Second International Workshop on HIV Drug Resistance. Noordwijk, The Netherlands1993: 18
        • Ho D.D.
        • Hartshorn K.L.
        • Rota T.R.
        • et al.
        Recombinant human interferon alpha suppresses HTLV-III replication in vitro.
        Lancet. 1985; 1: 602-604
        • Hodges T.I.
        • Kahn J.O.
        • Kaplan L.D.
        • et al.
        Phase I study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex.
        Antimicrob Agents Chemother. 1991; 35: 2580-2586
        • Hope T.J.
        • Klein N.P.
        • Elder M.E.
        • et al.
        Trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.
        J Virol. 1992; 66: 1849-1855
        • Hsu M-C
        • Schutt A.D.
        • Holly M.
        • et al.
        Human immunodeficiency virus Tat inhibitor.
        in: Mills J. Corey L. New Directions in Antiviral Therapy. Elsevier, New York1992: 289-300
        • Hsu M.C.
        • Schutt A.D.
        • Holly M.
        • et al.
        Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.
        Science. 1991; 254: 1799-1802
        • Hussey R.E.
        • Richardson N.E.
        • Kowalski M.
        • et al.
        A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
        Nature (London). 1988; 331: 78-81
        • Jacobson H.
        • Craig C.J.
        • Duncan I.B.
        • et al.
        Cell culture-selection and characterization of variant HIV-1 with reduced sensitivity to an inhibitor of the viral protease.
        J Cell Biochem. 1993; 17E: 90
        • Johnson D.R.
        • Cox A.D.
        • Solski P.A.
        • et al.
        Functional analysis of protein N- myristoylation: Metabolic labeling studies using three oxygen-substituted analogs of myristic acid and cultured mammalian cells provide evidence for protein-sequence-specific incorporation and analog-specific redistribution.
        Proc Natl Acad Sci USA. 1990; 87: 8511-8515
        • Johnson V.A.
        • Barlow M.A.
        • Chou T-C
        • et al.
        Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3′-azido-3′-deoxythymidine.
        J Infect Dis. 1989; 161: 1059-1067
        • Johnson V.A.
        • Merrill D.P.
        • Chou T.C.
        • et al.
        Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-αA against zidovudine-sensitive or-resistant HIV-1 in vitro.
        J Infect Dis. 1992; 166: 1143-1146
        • Kageyama S.
        • Mimoto T.
        • Murakawa Y.
        • et al.
        In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
        Antimicrob Agents Chemother. 1993; 37: 810-817
        • Kageyama S.
        • Weinstein J.N.
        • Shirasaka T.
        • et al.
        In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.
        Antimicrob Agents Chemother. 1992; 36: 926-933
        • Kahn J.O.
        • Allan J.D.
        • Hodges T.L.
        • et al.
        The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
        Ann Intern Med. 1990; 112: 254-261
        • Kaminchik J.
        • Bashan N.
        • Itach A.
        • et al.
        Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells.
        J Virol. 1991; 65: 583-586
        • Kao S.Y.
        • Caiman A.F.
        • Luciw P.A.
        • et al.
        Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.
        Nature (London). 1987; 330: 489-493
        • Kaplan A.H.
        • Zack J.A.
        • Knigge M.
        • et al.
        Partial inhibition of the human immunodeficiency virus type I protease results in aberrant virus assembly and the formation of noninfectious particles.
        J Virol. 1993; 67: 4050-4055
        • Karpas A.
        • Fleet G.W.
        • Durek R.A.
        • et al.
        Aminosugar derivatives as potential antihuman immunodeficiency virus agents.
        Proc Natl Acad Sci USA. 1988; 85: 9229-9233
        • Kempf D.J.
        • Marsh K.C.
        • Paul D.A.
        • et al.
        Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
        Antimicrob Agents Chemother. 1991; 35: 2209-2214
        • Kempf D.J.
        • Norbeck D.W.
        • Codacovi L.
        • et al.
        Structure-based C2 symmetric inhibitors of HIV protease.
        J Med Chem. 1990; 33: 2687-2689
        • Klatzmann D.
        • Champagne E.
        • Chamaret S.
        • et al.
        T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
        Nature (London). 1984; 312: 767-768
        • Kohl N.E.
        • Emini E.A.
        • Schleif W.A.
        • et al.
        Active human immunodeficiency virus protease is required for viral infectivity.
        Proc Natl Acad Sci USA. 1988; 85: 4686-4690
        • Koizumi M.
        • Iwai S.
        • Ohtsuka E.
        Cleavage of specific sites of RNA by designed ribozymes.
        FEBS Letters. 1988; 239: 285-288
        • Kornbluth R.S.
        • Oh P.S.
        • Munis J.R.
        • et al.
        Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro.
        J Exp Med. 1989; 169: 1137-1151
        • Kornbluth R.S.
        • Oh P.S.
        • Munis J.R.
        • et al.
        The role of interferons in the control of HIV replication in macrophages.
        Clin Immunol Immunopathol. 1990; 54: 200-219
        • Kort J.J.
        • Bilello J.A.
        • Bauer G.
        • et al.
        Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the HIV type 1 protease.
        Antimicrob Agents Chemother. 1993; 37: 115-119
        • Kotin K.M.
        • Siniscalo M.
        • Samulski J.
        • et al.
        Site-specific integration of adeno-associated virus (AAV) into human chromosome 19.
        EMBO J. 1990; 10: 3941-3950
        • Kovacs J.A.
        • Deyton L.
        • Davey R.
        • et al.
        Combined zidovudine and interferon alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS).
        Ann Intern Med. 1989; 111: 280-287
        • Krausslich H.G.
        Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.
        J Virol. 1992; 66: 567-572
        • Krown S.E.
        • Gold J.W.M.
        • Niedzwiecki D.
        • et al.
        Interferon with zidovudine: Safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
        Ann Intern Med. 1990; 112: 812-821
        • Lane H.C.
        • Davey V.
        • Kovacs J.A.
        • et al.
        Interferon-a in patients with asymptomatic human immunodeficiency virus (HIV) infection: A randomized, placebo-controlled trial.
        Ann Intern Med. 1990; 112: 805-811
        • Lane H.C.
        • Feinberg J.
        • Davey V.
        • et al.
        Antiretroviral effects of interferon-a in AIDS-associated Kaposi’s sarcoma.
        Lancet. 1988; 2: 1218-1222
        • Lapatto R.
        • Blundell T.
        • Hemmings A.
        • et al.
        X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes.
        Nature (London). 1989; 342: 299-302
        • Lavie G.
        • Valentine F.
        • Levin B.
        • et al.
        Studies of the mechanism of action of the antiretroviral agents hypericin and pseudohypericin.
        Proc Natl Acad Sci USA. 1989; 86: 5963-5967
        • Lee T.C.
        • Sullenger B.A.
        • Gallardo H.F.
        • et al.
        Overexpression of RRE-derived sequence inhibits HIV-1 replication in CEM cells.
        New Biol. 1992; 4: 66-74
        • Lenard J.
        • Rabson A.
        • Vanderoef R.
        Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation.
        Proc Natl Acad Sci USA. 1993; 90: 158-162
        • Lewis P.
        • Hensel M.
        • Emerman M.
        Human immunodeficiency virus infection of cells arrested in the cell cycle.
        EMBO J. 1992; 11: 3053-3058
        • Lisziewicz J.
        • Sun D.
        • Klotman M.
        • et al.
        Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment.
        Proc Natl Acad Sci USA. 1992; 89: 11209-11213
        • Lisziewicz J.
        • Sun D.
        • Smythe J.
        • et al.
        Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.
        Proc Natl Acad Sci USA. 1993; 90: 8000-8004
        • Maddon P.J.
        The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
        Cell. 1986; 47: 333-348
        • Majumdar C.
        • Stein C.A.
        • Cohen J.S.
        • et al.
        Stepwise mechanism of HIV reverse transcriptase primer function of phosphorothioate oligodeoxynucleotide.
        Biochemistry. 1989; 28: 1340-1346
        • Malim M.H.
        • Freimuth W.W.
        • Liu J.
        • et al.
        Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.
        J Exp Med. 1992; 176: 1197-1201
        • Malim M.H.
        • Hauber J.
        • Le S-Y
        • et al.
        The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.
        Nature (London). 1989; 338: 254-257
        • Marasco W.A.
        • Haseltine W.A.
        • Chen S.
        Design, intracellular expression, and activity of a human antihuman immunodeficiency virus type-1 gpl20 single-chain antibody.
        Proc Natl Acad Sci USA. 1993; 90: 7889-7893
        • Marciniak R.A.
        • Calnan B.J.
        • Frankel A.D.
        • et al.
        HIV-1 Tat protein transactivates transcription in vitro.
        Cell. 1990; 63: 791-802
        • Marcowitz D.
        • Goff S.
        • Bank A.
        Construction and use of a safe and efficient amphotropic packaging cell line.
        Virology. 1988; 167: 400-406
        • Markowitz D.
        • Goff S.
        • Bank A.
        A safe packaging line for gene transfer: Separating viral genes on two different plasmids.
        J Virol. 1988; 62: 1120-1124
        • Marshall W.S.
        • Beaton G.
        • Stein C.A.
        • et al.
        Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidirie.
        Proc Natl Acad Sci USA. 1992; 89: 62-6269
        • Marshall W.S.
        • Caruthers M.H.
        Phosphorodithioate DNA as a potential therapeutic drug.
        Science. 1993; 259: 1564-1570
        • Matsukura M.
        • Shinozuka K.
        • Zon G.
        • et al.
        Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus.
        Proc Natl Acad Sci USA. 1987; 84: 7706-7710
        • Matsukura M.
        • Zon G.
        • Shinozuka K.
        • et al.
        Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.
        Proc Natl Acad Sci USA. 1989; 86: 4244-4248
        • Matsukura M.
        • Zon G.
        • Shinozuka K.
        • et al.
        Synthesis of phosphorothioated analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
        Gene. 1988; 72: 343-347

      124. Mazzulli T, Chow YK, Merrill DP, et al: Combination therapy of HIV-1 infection in vitro: Convergent versus divergent drug regimens [abstract PO-B26-2082]. In Program and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 482

        • Meek T.D.
        • Lambert D.M.
        • Dreyer G.B.
        • et al.
        Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
        Nature (London). 1990; 343: 90-92
        • Mermer B.
        • Felber B.K.
        • Campbell M.
        • et al.
        Identification of trans-dominant HIV-1 Rev protein mutants by direct transfer of bacterially produced proteins into human cells.
        Nucleic Acids Res. 1990; 18: 2037-2044
        • Meruelo D.
        • Lavie G.
        • Lavie D.
        Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: Aromatic polycyclic diones hypericin and pseudohypericin.
        Proc Natl Acad Sci USA. 1988; 85: 5230-5234
        • Mervis R.J.
        • Ahmad N.
        • Lillehei E.P.
        • et al.
        The gag gene products of human immunodeficiency virus type 1: Alignment within the gag open reading frame, identification of post-translational modifications and evidence for alternative gag precursors.
        J Virol. 1988; 62: 3993-4002
        • Michael S.F.
        • Kaplan A.
        • Kempf D.
        • et al.
        Selection of HIV-1 mutants with resistance to a protease inhibitor.
        in: Program and Abstracts of the Second International Workshop on HIV Drug Resistance. Noordwijk, The Netherlands1993: 19
        • Miller D.G.
        • Adams A.
        • Miller A.D.
        Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.
        Mol Cell Biol. 1990; 10: 4239-4242
        • Miller M.
        • Jaskolski M.
        • Rao J.K.M.
        • et al.
        Crystal structure of a retroviral protease proves relationship to aspartic protease family.
        Nature (London). 1989; 337: 576-579
        • Moore J.P.
        • McKeating J.A.
        • Huang Y.
        • et al.
        Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp 120 retention from sCD4-sensitive isolates.
        J Virol. 1992; 66: 235-243
        • Muro-Cacho C.A.
        • Samulski R.J.
        • Kaplan D.
        Gene transfer in human lymphocytes using a vector based on adeno-associated virus.
        J Immunother. 1992; 11: 231-237
        • Navia M.A.
        • Fitzgerald P.M.D.
        • McKeever B.M.
        • et al.
        Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1.
        Nature. 1989; 337: 615-620
        • Ojwang J.O.
        • Hampel A.
        • Looney D.J.
        • et al.
        Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.
        Proc Natl Acad Sci USA. 1992; 89: 10802-10806
        • Pal R.
        • Kalyanaraman V.S.
        • Hoke G.M.
        • et al.
        Processing and secretion of envelope glycoprotein of human immunodeficiency virus type 1 in the presence of trimming glucosidase inhibitor deoxynojirimycin.
        Intervirology. 1989; 30: 27-35
        • Pal R.
        • Reitz Jr, M.S.
        • Tschachler E.
        • et al.
        Myristylation of gag proteins of HIV-1 plays an important role in virus assembly.
        AIDS Res Hum Retroviruses. 1990; 6: 721-730
        • Pearson L.
        • Garcia J.
        • Wu F.
        • et al.
        Transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
        Proc Natl Acad Sci USA. 1990; 87: 5079-5083
        • Peng C.
        • Ho B.K.
        • Chang T.W.
        • et al.
        Role of human immunodeficiency virus type I specific protease in core maturation and viral infectivity.
        J Virol. 1989; 63: 2550-2556
        • Pidgeon C.
        • Markovich R.J.
        • Liu M.D.
        • et al.
        Antiviral phospholipids: Anti-HIV drugs conjugated to the glycerobackbone of phospholipids.
        J Biol Chem. 1993; 268: 7773-7778
        • Poli G.
        • Orenstein J.M.
        • Kinter A.
        • et al.
        Interferon-a but not AZT suppresses HIV expression in chronically infected cell lines.
        Science. 1989; 244: 575-577
        • Poznansky M.
        • Lever A.
        • Bergeron L.
        • et al.
        Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector.
        J Virol. 1991; 65: 532-536
        • Priel E.
        • Showalter S.D.
        • Blair D.G.
        Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of campothecin, a topoisomerase I inhibitor.
        AIDS Res Hum Retroviruses. 1991; 7: 65-72
        • Ratner L.
        Glucosidase inhibitors for treatment of HIV-1 infection.
        AIDS Res Hum Retroviruses. 1992; 8: 165-173
        • Ratner L.
        • Vander Heyden N.
        Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
        AIDS Res Hum Retroviruses. 1993; 9: 291-297
        • Ratner L.
        • Vander Heyden N.
        • Dedera D.
        Inhibition of HIV and SIV infectivity by an inhibitor of oligosaccharide processing.
        Virology. 1991; 181: 180-192
        • Rhodes A.
        • James W.
        Inhibition of heterologous strains of HIV by antisense RNA.
        AIDS. 1990; 5: 145-151
        • Rhodes A.
        • James W.
        Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA.
        J Gen Virol. 1990; 71: 1965-1974
        • Roberts N.A.
        • Martin J.A.
        • Kinchingdon D.
        • et al.
        Rational design of peptide-based HIV proteinase inhibitors.
        Science. 1990; 248: 358-361
        • Robins T.
        • Plattner J.
        HIV protease inhibitors: Their anti-HIV activity and potential role in treatment.
        J AIDS. 1993; 6: 162-170
        • Rosen C.A.
        HIV regulatory proteins: Potential targets for therapeutic intervention.
        AIDS Res Hum Retroviruses. 1992; 8: 175-181
        • Roy S.
        • Delling U.
        • Chen C.H.
        • et al.
        A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.
        Genes Dev. 1990; 4: 1365-1373

      153. Rusconi S, Zhang D, Patch R, et al: In vitro inhibition of HIV-1 by a new class of CD4-binding drugs [WS-A17-1]. In Program and Abstracts of the IXth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, p 33

        • Sarin P.S.
        • Agrawal S.
        • Civeira M.P.
        • et al.
        Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates.
        Proc Natl Acad Sci USA. 1988; 85: 7448-7451
        • Sarver N.
        • Cantin E.M.
        • Chang P.S.
        • et al.
        Ribozymes as potential anti-HIV-1 therapeutic agents.
        Science. 1990; 247: 1222-1225
        • Saxena S.K.
        • Ackerman E.J.
        Ribozymes correctly cleave a model substrate and endogenous RNA in vivo.
        J Biol Chem. 1990; 265: 17106-17109
        • Schooley R.T.
        • Merigan T.C.
        • Gaut P.
        • et al.
        Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: A phase I-II escalating dosage trial.
        Ann Intern Med. 1990; 112: 247-253
        • Sczakiel G.
        • Pawlita M.
        • Kleinheinz A.
        Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5′ leader/gag region.
        Biochem Biophys Res Commun. 1991; 169: 643-651
        • Sharp P.A.
        • Marciniak R.A.
        HIV TAR: An RNA enhancer?.
        Cell. 1989; 59: 229-230
        • Sherman P.A.
        • Dickson M.L.
        • Fyfe J.A.
        Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions.
        J Virol. 1992; 66: 3593-3601
        • Shimada T.
        • Fujii H.
        • Mitsuya H.
        • et al.
        Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector.
        J Clin Invest. 1991; 88: 1043-1047
        • Shirazi Y.
        • Pitha P.M.
        Alpha-interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle.
        J Virol. 1992; 66: 1321-1328
        • Shirazi Y.
        • Pitha P.M.
        Interferon a-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells.
        Virology. 1993; 193: 303-312
        • Singh M.
        • Toyoshima T.
        • Markowitz M.
        • et al.
        Characterization of viral mutants resistant to a C2-symmetric inhibitor of HIV-1 protease.
        J Cell Biochem. 1993; 17E: 86
        • Sioud M.
        • Drlica K.
        Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme.
        Proc Natl Acad Sci USA. 1991; 88: 7303-7307
        • Smith D.N.
        • Byrn R.A.
        • Masters S.A.
        • et al.
        Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.
        Science. 1987; 238: 1704-1707
        • Smith M.S.
        • Thresher R.J.
        • Pagano J.S.
        Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.
        Antimicrob Agents Chemother. 1991; 35: 62-67
        • Stein C.A.
        • Matsukura M.
        • Subasinghe C.
        • et al.
        Phosphorothioate oligodeoxynucleotides are potent sequence specific inhibitors of de novo infection by HIV.
        AIDS Res Hum Retroviruses. 1989; 5: 639-646
        • Sullenger B.A.
        • Gallardo H.F.
        • Ungers G.E.
        • et al.
        Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.
        Cell. 1990; 63: 601-608
        • Sullenger B.A.
        • Gallardo H.F.
        • Ungers G.E.
        • et al.
        Analysis of trans-acting response decoy RNA-mediated inhibition of HIV type 1 transactivation.
        J Virol. 1991; 65: 6811-6816
        • Till M.A.
        • Ghetie V.
        • May R.D.
        • et al.
        Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.
        J AIDS. 1990; 3: 609-614
        • Towler D.A.
        • Eubanks S.R.
        • Towet D.S.
        • et al.
        Amino-terminal processing of proteins by N-myristoylation: Substrate specificity of N-myristyl transferase.
        J Biol Chem. 1987; 262: 1030-1036
        • Traunecker A.
        • Luke W.
        • Karjalainen K.
        Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
        Nature (London). 1988; 331: 84-86
        • Traunecker A.
        • Schneider J.
        • Keifer H.
        • et al.
        Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
        Nature (London). 1989; 339: 68-70
        • Trono D.
        • Feinberg M.B.
        • Baltimore D.
        Gag mutants can dominantly interfere with the replication of the wild-type virus.
        Cell. 1989; 59: 113-120
        • Uhlenbeck O.C.
        A small catalytic oligoribonucleotide.
        Nature. 1987; 328: 596-600
        • Veronese F.D.
        • Copeland T.D.
        • Oroszlan S.
        • et al.
        Biochemical and immunological analysis of human immunodeficiency virus gag gene products pl7 and p24.
        J Virol. 1988; 62: 795-801
        • Walker B.D.
        • Kowalski M.
        • Goh W.C.
        • et al.
        Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.
        Proc Natl Acad Sci USA. 1987; 84: 8120-8124
        • Weber I.T.
        • Miller M.
        • Jaskolski M.
        • et al.
        Molecular modeling of the HIV-1 protease and its substrate binding site.
        Science. 1989; 243: 928-931
        • Wehbie R.
        • Pettie S.
        • Michael S.
        • et al.
        Kinetic characteristics of HIV-1 protease mutants resistant to the protease inhibitor A77003.
        in: Program and Abstracts of the Second International Workshop on HIV Drug Resistance. Noordwijk, The Netherlands1993: 20
        • Weinberg J.B.
        • Mathews T.J.
        • Cullen B.R.
        • et al.
        Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes.
        J Exp Med. 1991; 174: 1477-1482
        • Wells D.E.
        • Chatterjee S.
        • Mulligan M.J.
        • et al.
        Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons.
        J Virol. 1991; 65: 168-172
        • Wilcox C.
        • Hu J.S.
        • Olson E.N.
        Acylation of proteins with myristic acid occurs cotranslationally.
        Science. 1987; 238: 1275-1278
        • Wlodawer A.
        • Miller M.
        • Jaskolski M.
        • et al.
        Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease.
        Science. 1989; 245: 616-621
        • Yamamoto J.K.
        • Barre-Sinoussi F.
        • Bolton V.
        • et al.
        Human alpha-and beta-interferon but not gamma suppress the in vitro replication of LAV, HTLV-111, and ARV-2.
        J Interferon Res. 1986; 6: 143-152
        • Yu G.
        • Felsted R.L.
        Effect of myristoylation on p27nef subcellular distribution and suppression of HIV-LTR transcription.
        Virology. 1992; 187: 46-55
        • Yu M.
        • Ojwang J.
        • Yamada O.
        • et al.
        A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.
        Proc Natl Acad Sci USA. 1993; 90: 6340-6344
        • Zaia J.A.
        • Rossi J.J.
        • Murakawa G.J.
        • et al.
        Inhibition of human immunodeficiency virus by using an oligonucleotide methylphosphonate targeted to the tat-3 gene.
        J Virol. 1988; 62: 3914-3917
        • Zamecnik P.C.
        • Goodchild J.
        • Taguchi Y.
        • et al.
        Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.
        Proc Natl Acad Sci USA. 1986; 83: 4143-4146
        • Zapp M.L.
        • Green M.R.
        Sequence-specific RNA binding by the HIV-1 Rev protein.
        Nature (London). 1989; 342: 714-716
        • Zapp M.L.
        • Stern S.
        • Green M.R.
        Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit rev function and viral production.
        Cell. 1993; 74: 1-10

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30384-6

      Copyright

      © 1994 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX